Related references
Note: Only part of the references are listed.Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Laura Keller et al.
BRITISH JOURNAL OF CANCER (2021)
Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
Jose Maria Piulats et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Gillian Vandekerkhove et al.
NATURE COMMUNICATIONS (2021)
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
Meredith S. Pelster et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
Wei Zou et al.
JCO PRECISION ONCOLOGY (2021)
Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Laurent Dercle et al.
CLINICAL CANCER RESEARCH (2020)
Molecular profiling of driver events in metastatic uveal melanoma
Joakim Karlsson et al.
NATURE COMMUNICATIONS (2020)
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R. Middleton et al.
CLINICAL CANCER RESEARCH (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman et al.
NATURE CANCER (2020)
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
L. Khoja et al.
ANNALS OF ONCOLOGY (2019)
The genetic evolution of metastatic uveal melanoma
A. Hunter Shain et al.
NATURE GENETICS (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis
Elina S. Rantala et al.
MELANOMA RESEARCH (2019)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Uveal Melanoma: A Review of the Literature
Manni Singh et al.
ONCOLOGY AND THERAPY (2018)
Treatment of uveal melanoma: where are we now?
Jessica Yang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
Rajiv Raja et al.
CLINICAL CANCER RESEARCH (2018)
Metastatic disease from uveal melanoma: treatment options and future prospects
Richard D. Carvajal et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
Caroline Boudousquie et al.
IMMUNOLOGY (2017)
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma
Asad Javed et al.
IMMUNOTHERAPY (2017)
Systematic genomic and translational efficiency studies of uveal melanoma
Chelsea Place Johnson et al.
PLOS ONE (2017)
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.
Takami Sato et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
A. Gordon Robertson et al.
CANCER CELL (2017)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
Mark R. Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
Giovanna Bossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Adaptation and modification of the immune related response criteria (IRRC): IrRECIST
Oliver Bohnsack et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
Marcel Martin et al.
NATURE GENETICS (2013)
Monoclonal TCR-redirected tumor cell killing
Nathaniel Liddy et al.
NATURE MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
S. O'Day et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Incidence of uveal melanoma in Europe
Gianni Virgili et al.
OPHTHALMOLOGY (2007)
International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification
A Stang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Nonparametric estimation of average treatment effects under exogeneity: A review
GW Imbens
REVIEW OF ECONOMICS AND STATISTICS (2004)
Very long-term prognosis of patients with malignant uveal melanoma
E Kujala et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
Share Paper
